AGRX Agile Therapeutics, Inc.

2.48
+0.01  (0.4%)
Previous Close 2.47
Open 2.46
Price To book 1.52
Market Cap 71.32M
Shares 28,757,000
Volume 98,796
Short Ratio 0.52
Av. Daily Volume 609,418

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued 2013. Phase 3 top-line data released January 3, 2017 - poor data but intends to reflile NDA 1H 2017.
Twirla
Contraceptive patch

Latest News

  1. IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  2. Lawsuit for Investors in NASDAQ: AGRX Shares against Agile Therapeutics Inc. Announced by Shareholders Foundation
  3. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  4. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agile Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AGRX
  5. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  6. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Agile Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 7, 2017 – AGRX
  7. SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  8. AGRX NOTICE: Rosen Law Firm Reminds Agile Therapeutics Investors of Important Class Action Deadline – AGRX
  9. IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  10. SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Agile Therapeutics, Inc. (AGRX) and Lead Plaintiff Deadline: March 7, 2017
  11. Agile Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference
  12. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  13. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  14. AGRX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Agile Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017
  15. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agile Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AGRX
  16. SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  17. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In Agile Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline
  18. IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  19. March 7 Deadline Alert: Law Offices of Howard G. Smith Reminds Agile Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
  20. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm